Table 1 Characteristics of study sample by treatment group
Platinum | Taxane | Platinum plus Taxane | Other | P | |
|---|---|---|---|---|---|
Contrast-enhanced CTs, n | 1249 | 385 | 182 | 2129 | |
Median duration of treatment, d [range] | 70 [1–502] | 77 [1–483] | 50 [1–258] | 73 [1–707] | < 0.0001 |
Mean no. of CTs per patient (SD) | 1.72 (1.07) | 2.18 (1.59) | 1.55 (0.78) | 2.42 (1.82) | < 0.0001 |
Median patient age at CT, y [range] | 65 [18–87] | 64 [23–86] | 61 [23–80] | 66 [21–91] | < 0.0001 |
Primary tumor | |||||
Gastrointestinal | 618 (49.5%) | 12 (3.1%) | 27 (14.8%) | 541 (25.4%) | < 0.0001 |
Urogynecological | 160 (12.8%) | 129 (33.5%) | 115 (63.2%) | 266 (12.5%) | |
Breast | 47 (3.8%) | 176 (45.7%) | 8 (4.4%) | 523 (24.6%) | |
Lung | 305 (24.4%) | 50 (13%) | 10 (5.5%) | 271 (12.7%) | |
Hematological | 6 (0.5%) | 1 (0.3%) | 2 (1.1%) | 207 (9.7%) | |
Melanoma | 44 (3.5%) | - | 5 (2.8%) | 128 (6%) | |
Other sites | 69 (5.5%) | 17 (4.4%) | 15 (8.2%) | 193 (9.1%) | |
ICM-related ARs, n (%) | 9 (0.7) | 5 (1.3) | 4 (2.2) | 22 (1.0)* | 0.221 |